Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: The extraordinary safety measures that will govern the May 20-22 session were delineated in a letter Wednesday from Democratic House Speaker Michael Madigan to the House minority leader. Legislators will have to pledge to follow Illinois Department of Public Health guidelines to prevent the spread of the highly contagious and potentially lethal coronavirus. They include pre-session testing of all legislators for COVID-19. Eschewing the traditional Capitol setting, the House will be called to order six blocks away at the Bank of Springfield Center in downtown Springfield, to take advantage of the spacious convention center floor for social distancing. The Senate, whose membership is half the House’s 118 seats, will meet in its regular chamber, Senate President Don Harmon said in a statement. The Oak Park Democrat rallied senators to return to action with the “cooperative spirit of bipartisan achievement” they’ve shown before. “This global pandemic has decimated our state and local economies regardless of political affiliation,” Harmon said. “From far-flung living rooms, kitchen tables and home offices, senators have been working together — while apart — to figure out what we can and need to do now.” Legislators, whom Gov. J.B. Pritzker declared essential workers and not subject to his seven-week-old stay-at-home order scheduled to expire May 30, have nonetheless been absent from the Statehouse since early March to prevent spreading sickness. That period represents the heart of the Illinois General Assembly’s spring-session calendar, ending with a scheduled May 31 adjournment and typically a budget for the fiscal year that begins July 1. Pritzker implored lawmakers to help those left out of initial federal relief deals. “Lots of people fell through the cracks,” Pritzker said at his daily COVID-19 briefing in Chicago. Relief won’t come from the state treasury. Tax revenue lost because of the pandemic has opened a $7 billion deficit in the current budget and next year’s. Illinois will be dependent on the federal government, Pritzker said. “We need to rely upon federal government and its support for all the states in order for us to provide the services that people need or for us to pay for the education that our kids need, and for us to support our businesses and our families,” Pritzker said. Madigan’s letter to House GOP Leader Jim Durkin of Western Springs said all state representatives must pledge to abide by public health guidelines for safely congregating. In addition to pre-trip testing, they include agreeing to undergo body temperature checks upon entering the building for sessions, wearing provided face coverings whenever meeting with staff members or colleagues, avoiding outside meetings or social engagements, and undergoing another test upon returning home. It won’t be the first time lawmakers convened outside of the current Statehouse, which welcomed its first session in 1877. In recent history, the legislative chambers were undergoing renovation when then-Gov. George Ryan called a special session in the summer of 2000 to temporarily remove the state sales tax on gasoline during a price spike. Sessions were conducted in the auditorium of the Howlett Building next door to the Capitol. ___ Check out more of the AP’s coronavirus coverage at https://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak ___ Follow Political Writer John O’Connor at https://twitter.com/apoconnor Claim: Safety measures to govern Legislature’s return to capital.

Ex Output:
The Illinois General Assembly will return to Springfield for three days next week to take up a spring session workload long delayed by the coronavirus pandemic.


Ex Input:
Paragraph: Bryant’s action came despite a federal judge’s ruling last year that struck down a less-restrictive law limiting abortions in the state. The New York-based Center for Reproductive Rights called the new measure “cruel and clearly unconstitutional” and said it would sue Mississippi to try to block the law from taking effect on July 1. After a bill signing ceremony at the state Capitol, Bryant told reporters that he’s not worried about lawsuits. “They don’t have to sue us. It’s up to them,” Bryant said. “If they do not believe in the sanctity of life, these that are in organizations like Planned Parenthood, we will have to fight that fight. But it is worth it.” Mississippi is one of several states that have considered bills this year to ban abortions once a fetal heartbeat is found. Abortion opponents are emboldened by new conservatives on the Supreme Court and are seeking cases to challenge Roe v. Wade, the court’s 1973 ruling that legalized abortion nationwide. A federal judge in 2018 struck down a Mississippi law that would ban most abortions after 15 weeks of pregnancy, saying it is unconstitutional. The ruling came in a lawsuit filed by the only remaining abortion clinic in Mississippi. “Lawmakers didn’t get the message,” Hillary Schneller, staff attorney for the Center for Reproductive Rights, said in a statement Thursday. “They are determined to rob Mississippians of the right to abortion, and they are doing it at the expense of women’s health and taxpayer money. This ban — just like the 15-week ban the governor signed a year ago — is cruel and clearly unconstitutional.”  The law that Bryant signed Thursday says a physician who performs an abortion after a fetal heartbeat is detected could face revocation of his or her Mississippi medical license. It also says abortions could be allowed after a fetal heartbeat is found if a pregnancy endangers a woman’s life or one of her major bodily functions. The House and Senate both rejected efforts to allow exceptions for pregnancies caused by rape or incest. Georgia and Tennessee are among the states considering similar bills. Kentucky’s law banning abortion after the detection of a heartbeat was immediately challenged by the American Civil Liberties Union when Republican Gov. Matt Bevin signed it on March 14, and a federal judge temporarily blocked it. A federal judge on Wednesday also blocked another Kentucky law that would ban abortion for women seeking to end their pregnancies because of the gender, race or disability of the fetus. Dr. Leana Wen, a physician who is president of Planned Parenthood Federation of America, said in a statement Thursday that the new Mississippi law “is a dangerous policy that criminalizes a safe, standard medical procedure and will endanger women’s lives.” “Patients must be empowered to make their own health care decisions, in consultation with their doctor and their family, and doctors must be able to provide health care to our patients without the threat of prison time,” Wen said. “We cannot accept a world where the right to abortion care depends on where you live or how much money you make.” Jameson Taylor, vice president for policy at the conservative Mississippi Center for Public Policy, praised Bryant for signing the bill. “The heartbeat bill is popular because everyone knows a heartbeat is a sign of life,” Taylor said in a statement. “Intellectual and scientific honesty demands a reconsideration of Roe, a 50-year-old decision based on old science. 3-D and 4-D ultrasounds are showing women that their unborn child is alive.” ____ Follow Emily Wagster Pettus on Twitter at http://twitter.com/EWagsterPettus . Claim: Mississippi governor signs ‘heartbeat’ abortion law.

Ex Output:
Mississippi Gov. Phil Bryant on Thursday signed one of the strictest abortion laws in the nation — a measure that bans most abortions once a fetal heartbeat can be detected, about six weeks into pregnancy.


Ex Input:
Paragraph: “Pets are your loved ones, pets should be your family, pets are not something you keep on a chain in the backyard,” the intensive-care nurse from Somers, Connecticut, said. Lescault, 43, who enrolled Moose in a clinical trial of an experimental drug designed to help his immune system fight his  cancer, represents the type of pet lover that has spurred animal health companies around the globe to invest in developing complex new treatments previously reserved for humans. Biotechnology, which produces medicines from living cells, revolutionized the drug industry more than a quarter century ago with breakthrough medicines at prices that now run as high as hundreds of thousands of dollars a year. In recent years, the cost of genetic testing and biotech drug production has fallen sharply, making biotechnology for pets financially viable at much lower prices, industry experts said. For a FACTBOX, click  Sector leader Zoetis (ZTS.N) and others say animal drug development is faster, less expensive and more predictable than drugs for people. “It’s not nearly as common for pivotal studies to fail in animal health as it is in human medicine. Most of them are successful,” said Cheryl London, professor in comparative oncology at Cummings School of Veterinary Medicine at Tufts University in Massachusetts. Biotech drugs for pets, if proven safe and effective, would be a boon to a $44 billion veterinary medicines market currently dominated by vaccines, flea and tick repellents and anti-infectives. A recent product launch has galvanized the industry. Cytopoint for canine itch relief sold by Zoetis reached blockbuster status by animal health standards in its second year on the market. Launched in late 2016, Cytopoint generated 2018 sales of $129 million, and first-quarter 2019 sales jumped 65% from a year earlier. Produced from cloned genetically engineered hamster cells over at least eight bio-processing steps, the monoclonal antibody is no less complex than comparable therapeutic proteins used in human medicine. But the cost to consumers is far less. Like many biotech drugs, dose and cost is determined by weight. Zoetis declined to disclose its prices. But an animal hospital in Stamford, Connecticut, for example, charges $104 for a 40-pound (18 kg) dog. For much smaller dogs, a Cytopoint injection, which lasts about four to eight weeks, costs about $35 to $50. To keep a large dog from scratching itself raw could run $140 per shot. The cost of a highly effective new anti-itch biotech drug to treat severe atopic dermatitis in humans can run about $30,000 a year. “Cytopoint was a turning point that has made it clear that (biotech drugs) can be successful in this space,” London said. “Now there are an estimated five to ten companies developing antibodies for the veterinary market.”  That has created increased business for related services. “It’s a big challenge for us to keep up with the pace of demand growth,” said Klaus Hellmann, managing director at Munich-based Klifovet AG, Europe’s largest contractor for late-stage clinical trials of veterinary drugs. While Cytopoint sparked investment interest in biotech treatments for animals, drug development still comes with inherent risks and uncertainty. Aratana Therapeutics Inc’s canine lymphoma drug, Blontress, was launched in 2015, but later withdrawn after scientific data led the company to determine it was unlikely to be a financial success. Declining costs has mitigated some of the risk. “Over the past several years, human health has been able to advance the technology to improve efficiency of their cell production systems,” said Rob Polzer, head of global therapeutics research for Zoetis. Zoetis can repurpose and optimize existing procedures, mechanisms of action and technologies, it said. The company is seeking approval for a biotech medicine to treat osteoarthritic pain in cats, with plans for a 2021 market launch and a similar product for dogs thereafter. Others have jumped on the bandwagon. German start-up Adivo was spun out of biotech firm Morphosys (MORG.DE) in March 2018 out of frustration by its founders that scientific advances for humans were not translating into better treatment options for their dogs. It has since struck a global collaboration deal with Bayer’s (BAYGn.DE) animal health unit for its early-stage research platform for animal-specific monoclonal antibodies - the backbone of biotechnology. “Over the last few years, the veterinary market has seen an incredibly dynamic development,” said Adivo co-founder Kathrin Ladetzki-Baehs. This could prove a lifesaver for Moose, the bulldog in the oncology drug trial. In early August, Lescault discovered a mass on Moose’s  throat, soon followed by deteriorating health and a diagnosis of canine B-cell lymphoma. Moose was given one to two months to live without treatment or about a year with 25 weeks of punishing chemotherapy. Lescault’s local vet suggested the Tufts trial testing an experimental protein that could help advance the current immuno-oncology craze into the animal health arena. Tufts declined to disclose the compound or the study’s sponsor. But more than three weeks into the trial, Moose’s cough and labored breathing has disappeared and he is back to his playful and boisterous self, Lescault said. While treatment in a clinical trial is free, Lescault said she would not hesitate to pay thousands of dollars for a safe and effective drug to save Moose. “I wouldn’t blink an eye,”  she said. That is exactly what drug companies are banking on. Claim: Biotech is going to the dogs - and big profits await.

Ex Output:

For Jessica Lescault there is no question that her 6-year old English bulldog “Moose” deserves cutting-edge biotechnology cancer treatment as much as any human patient.